Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone

Naito, Seiji; Kotoh, Shuji; Omoto, Tetsuo; Osada, Yoshihito; Saito, Kazuyuki; Iguchi, Atsushi; Ariyoshi, Asami; Hiratsuka, Yoshiharu; Kumazawa, Joichi

doi:10.1007/s002800050831

Cited by 29 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were similar to previously reported findings [1- 14,22,23], In addition, the recurrence-free survival rate did not significantly differ according to tumsour size, pathological stage and concomitant CIS.…”

Section: Discussionsupporting

confidence: 94%

Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

Morabito¹,

Volpe²,

Rossi³

et al. 2004

UroOncology

View full text Add to dashboard Cite

The objectives of ihis study were to evaluate the effectiveness, the patients compliance and tolerahility to bacillus Calinette-Guerin (BCG) intravesical instillation after transurethral resection of bladder Uimour (TURBT) for stage Ta-Tl, grade G1-G3 transitional cell carcinoma (TCC) of the urinary bladder.Methods: BetVi-een January 1995 and May 2002, 127 patients (110 males and 17 females) aged between 40 and 81 years (mean ± SD 66.5 ± 8.4 years) with Ta-Tl. GI-G3 TCC of the urinary bladder were treated by TURBT and adjuvant intravesical instillation with BCG. The following details were recorded and evaluated: the disease-free survival rates, the tumour recurrence, age. gender, morphology, the size and number of tumours and side effects of BCG instillation.Results: Eighty (63%) and fourty seven (37%) patients were presented multifocality and monofocality at the baseline, respectively. Follow-up periods were 3-48 months (median. 18 months) for 110 of the 127 patients enrolled. At 3 months follow-up 40 multifocality patients (59,7%) and 27 monofocality patients (40.3%) were disease free. At 18 months follow-up, tumour disease-free survival rate was 63% while at 48 months we had 44 drop out and intravesical recurrence was noted in 43 patients (39.1%). We had 47 patients with side effects by BCG instillation in free disease patients and 15 in the not disease free ones, Twentyseven patients (40.3%) of the disease free patients had no side effects versus 28 patients (65,1%) in the not disease free ones. Of the patients. 28.3% were withdrawn for the side effects of therapy while 32.2% were discontinued for recurrence of disease.Conclusion: These findings confirm that intravesical instillation with BCG combined with TURBT is effective and safe for treatment of bladder cancer. This treatmeni facilitates bladder preservation by reducing recurrences and delaying the progression in many patients, however, further experience and longer follow-up studies of this treatment are required.

show abstract

Section: Discussionsupporting

confidence: 94%

Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

Morabito¹,

Volpe²,

Rossi³

et al. 2004

UroOncology

View full text Add to dashboard Cite

show abstract

“…A variety of new modalities, using technical adjuvant methods or modification of the cytotoxic drugs, have been investigated. Verapamil, a chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, increases the efficacy of adjuvant intravesical doxorubicin therapy when compared to doxorubicin alone (71). Modifying the structure of established cytotoxic drugs could also enhance their efficacy (72).…”

Section: Methods Of Treatmentmentioning

confidence: 99%

Prevention and Treatment of Urothelial Premalignant and Malignant Lesions

Wijkström

Cohen

Gardiner

et al. 2000

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

Bladder cancer is believed to develop through reversible premalignant stages followed by irreversible steps, and ending in invasive cancer giving rise to distant metastases. Because of the variation in the clinical course it has also been suggested that different forms of cancer develop along different molecular pathways leading to tumor presentations of various malignant potential. Today we treat and prognosticate bladder cancer on the basis of clinical and histologic findings that are insufficient to assess all the biologic potential of these tumors. Understanding the pathogenesis of bladder cancer might lead to a more precise identification of particular tumors with regard to clinical aggressiveness, resulting in individualized strategies for treatment and prophylaxis.Bladder cancer is seldom diagnosed in its preclinical stage, it is instead detected at cystoscopy and virtually never recognized as an incidental finding on autopsy. Therefore its "natural history" largely reflects that of "treated" disease. The true incidence of premalignant and malignant epithelial changes is not known. Incidences of hyperplasia and dysplasia of %10% and %5%, respectively and only occasional findings of cancer itself were reported in two autopsy series. Urothelial dysplasia is generally believed to be premalignant and a putative precursor of invasive cancer but unfortunately there has been a lack of standardization in terms of terminology and diagnosis. There is also a need for an agreed definition of the boundary between premalignancy, i.e. urothelial changes that have some but not all the features of carcinoma in situ, and malignancy, especially when considering potentially harmful treatments to prevent this transition. Most new diagnostic tools available and being tested today compare new detection techniques with traditional methods such as cytology or conventional histology of malignant rather than premalignant changes. There is probably also a short preclinical latency, as implied by the incidental findings of bladder cancer at autopsy, which makes it necessary to define how and when to promote early detection and treatment.Future studies therefore have to concentrate on methods for early detection of disease as well as characterization of host susceptibility, evaluation of exposure to carcinogens and potential effects of preventive measures. It is also likely that the improved tools of molecular prognostication will allow us to design trials more precisely in order to tailor therapeutic strategies.

show abstract

“…The rate of complete disappearance increased in proportion to the concentration of ADM and the duration of retention of the drug. However, ADM caused local side effects dependent on both the drug concentration and the duration of drug retention [7][8][9][10]. Carboplatin, paclitaxel, and irinotecan are potent anticancer chemotherapy drugs commonly used in the treatment of many solid tumors.…”

Section: Introductionmentioning

confidence: 99%

Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models

et al. 2012

View full text Add to dashboard Cite

The aim of this study was to establish xenograft models of tumor in mice bladder and evaluate the antitumor efficacy of ampelopsin sodium (Amp-Na). A total of 2×10 human bladder carcinoma EJ cells and murine sarcoma 180 cells were instilled into the bladder of BALB/c nu/nu mice and Swiss mice after preconditioning to establish the tumor model. Mice bearing orthotopic tumors were treated with Amp-Na by intravenous, intraperitoneal, or intravesical instillation. In addition, the pharmacokinetics property of Amp-Na was investigated in normal BALB/c mice. Our results showed that Amp-Na was excreted mainly through the urine, where it existed at a high concentration. Amp-Na significantly inhibited the proliferation of EJ and sarcoma 180 cells both in vivo and in vitro and this can be at least partially attributed to the cell cycle arrest induced by Amp-Na. This study suggests that the use of Amp-Na is an attractive chemotherapeutic modality for bladder cancer patients.

show abstract

Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone

Abstract: Intravesical instillation chemotherapy with ADM plus VR was found to have a significantly greater beneficial effect than with ADM alone for preventing recurrence after TUR of superficial bladder cancer.

Cited by 29 publications

References 8 publications

Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

Prevention and Treatment of Urothelial Premalignant and Malignant Lesions

Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models

Contact Info

Product

Resources

About